A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy - STELLAR Study

ORBUS THERAPEUTICS INC.0 个研究点目标入组 280 人开始时间: 2018年4月20日最近更新: 2019年4月30日

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方
入组人数: 280

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

入选标准

•Patients must meet all of the following inclusion criteria to be eligible for participation in this study:
•1. The ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures.
•2. Age = 18 years.
•3. Surgical or biopsy-proven diagnosis of WHO grade 3 AA.
•4. Unequivocal evidence of first AA tumor progression or recurrence = 3 months prior to randomization based on MRI criteria for tumor progression using enlarging Gd-contrast enhancement and/or T2 hypersensitivity (Appendix 4). Patients with non-measurable Gd-contrast enhancing tumors will only be eligible if there is no necrosis seen on MRI and/or histopathological confirmation of AA per standard of care procedures is obtained within 4 weeks prior to randomization.
•5. First tumor progression or recurrence following surgical resection or biopsy, if resection is not feasible, EBRT and temozolomide chemotherapy.
•6. Completion of EBRT = 6 months prior to randomization.
•7. Stained, unstained slides or tumor tissue block(s) are available from their most recent tumor surgery are available for central histological confirmation.
•8. A patient whose AA tumor has progressed or recurred and has had another surgical resection prior to randomization will be eligible if a) pathology review confirms AA, b) post-surgical MRI demonstrates measurable tumor on T2/FLAIR, and c) MRI performed after surgery is within 4 weeks prior to randomization.
•9. If taking corticosteroids, must be on a stable or decreasing dose for at least 5 days prior to the screening MRI.
•10. Karnofsky Performance Status (KPS) score of > 70.
•11. Off anticancer therapy for at least 4 weeks and recovered from any significant treatment-related toxicities to Grade = 1 prior to randomization.
•12. Adequate recovery from any major surgery is required; at least 4 weeks must have elapsed from the time of any major surgery and must have recovered from all surgery-related toxicities to Grade = 1 prior to randomization.
•13. Adequate hematologic function (ANC = 1,500/µL, platelet count = 100,000/µL, and hemoglobin = 10.5 gm/dL) within 14 days prior to randomization.
•14. Total bilirubin = 1.5x upper limit of normal (ULN) within 14 days prior to randomization.
•15. Hepatic transaminases (AST and ALT) = 2x ULN within 14 days prior to randomization.
•16. Adequate renal function (serum creatinine = 1.5x ULN) within 14 days prior to randomization.
•17. Life expectancy = 6 months.
•18. Female patients of childbearing potential must agree to utilize acceptable contraceptive methods from screening throughout the duration of the study period, and for 30 days following the last dose of study drug. Abstinence is an acceptable method of contraception. Otherwise, consistent and current use of 1 of the following methods of birth control is accepted: oral contraceptive, intrauterine device (IUD), intrauterine hormone-releasing system (IUS), tubal sterilization, Essure micro-insert system, or vasectomy in the male partner. Female patients must also refrain from egg donation and in vitro fertilization during treatment and until at least 30 days from the last dose of study drug.
•19. Male patie

排除标准

•Patients who meet any of the following exclusion criteria are not eligible for study participation:
•1. MRI defining progression is consistent with a diagnosis of glioblastoma or radiation necrosis.
•2. Patients who are considered to be refractory to EBRT and temozolomide but who have not progressed.
•3. Prior systemic therapy for recurrence of AA.
•4. Presence of extracranial or leptomeningeal disease.
•5. Prior lomustine use.
•6. History of other invasive malignancy, unless adequately treated with curative intent and with no known active disease present within 2 years prior to the first dose of study drug. Patients with non-melanoma skin cancer, carcinoma in situ (including superficial bladder cancer), cervical intraepithelial neoplasia and organ-confined prostate cancer deemed by the investigator to be at low risk of recurrence are not excluded.
•7. Active infection or serious intercurrent medical illness.
•8. Known to be HIV positive or to have an AIDS-related illness, Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) positive.
•9. Poorly controlled epilepsy.
•10. Unable to undergo an MRI with contrast.
•11. Uncontrolled or severe cardiovascular disease, including myocardial infarction or unstable angina within 6 months prior to study treatment, New York Heart Association (NYHA) Class III or IV congestive heart failure, serious arrhythmias requiring medication for treatment, clinically significant pericardial disease, or cardiac amyloidosis.
•12. Malabsorption syndrome, history of resection of the stomach or small bowel, active ulcerative colitis or Crohn’s disease, or partial or complete bowel obstruction or other conditions that would be expected to alter the absorption or PK of study drugs.
•13. Receipt of any other anticancer therapy while receiving protocol-defined therapy.
•14. Concurrent use of any other investigational agent during the study or within 30 days prior to randomization.
•15. Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the patient unsuitable for the study.
•16. Pregnant or breastfeeding.

研究者

发起方

ORBUS THERAPEUTICS INC.

相似试验

进行中（未招募）

1 期

A study to measure how well and how safe eflornithine is in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has got worse or come back after radiation and chemotherapy.Anaplastic AstrocytomaMedDRA version: 21.0Level: PTClassification code 10002224Term: Anaplastic astrocytomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2016-000089-45-GBOrbus Therapeutics, Inc.340

招募中

3 期

A Phase 3, Randomized, Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy<br>Anaplastic Astrocytoma - Rare malignant brain tumor10029211

NL-OMON50263Orbus Therapeutics, Inc.16

进行中（未招募）

1 期

EUCTR2016-000089-45-BEOrbus Therapeutics, Inc.340

进行中（未招募）

1 期

A study to measure how well and how safe eflornithine is in combination with lomustine, compared to lomustine taken alone, in treating patients whose anaplastic astrocytoma has got worse or come back after radiation and chemotherapy.Anaplastic AstrocytomaMedDRA version: 19.1Level: PTClassification code 10002224Term: Anaplastic astrocytomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2016-000089-45-NLOrbus Therapeutics, Inc.280

进行中（未招募）

1 期

EUCTR2016-000089-45-DEOrbus Therapeutics, Inc.340